Charles River Laboratories and Toxys Enter Agreement to Offer ToxTracker® in North America

Charles River will offer access to ToxTracker®, expanding the
Company’s portfolio of genetic toxicology assays

WILMINGTON, Mass. & LEIDEN, The Netherlands–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;$CRLlt;/agt; lt;a href=”” target=”_blank”gt;#LIFEatCRLlt;/agt;–Charles River Laboratories International, Inc (NYSE: CRL) and Toxys have
entered into an agreement to offer access to ToxTracker® in North
America. ToxTracker is a suite of assays that allow rapid
carcinogenicity toxicity hazard identification in novel and existing
drugs, chemicals, and other substances.

With an extremely high level of sensitivity and specificity, ToxTracker
can be used to quickly screen chemicals for genotoxicity. By combining
multiple biomarkers, ToxTracker provides mechanistic insight into
undesired properties of compounds.

The assay identifies various toxic properties of chemicals that have
been associated with increased cancer risk through both traditional
markers, such as DNA damage, and alternative Modes-of-Action, including
oxidative stress and protein damage. For Charles River’s clients,
utilization of the ToxTracker assay can help mitigate risk of regulatory
rejection by demonstrating the exact mechanism of genotoxicity.

ToxTracker has been extensively validated using reference compound
libraries recommended by the United States Environmental Protection
Agency’s Toxicity Forecaster (ToxCast) and the European Union Reference
Laboratory for alternatives to animal testing (EURL ECVAM). Through this
validation, ToxTracker has shown a very high sensitivity (94%) and
specificity (95%) for the detection of genotoxic compounds.
Additionally, ToxTracker’s versatility in identifying unsafe compounds
provides applications across the pharmaceutical, agrochemical and
consumer product industries.

Approved Quotes

  • “We are proud to work with Toxys to expand our portfolio of genetic
    toxicology assays. By providing our clients with access to the
    ToxTracker assays, we are improving their ability to deliver safe,
    effective compounds.” –Birgit Girshick, Corporate Executive Vice
    President, Discovery and Safety Assessment of Charles River
  • “When looking for a company to provide ToxTracker to the North
    American market, Charles River was an easy choice. Their deep industry
    knowledge and experience, coupled with an already robust portfolio of
    toxicology services, makes them the ideal partner for our innovative
    assays. We are excited to work together to bring ToxTracker to a wider
    audience.” –Giel Hendriks, CEO of Toxys

About Toxys 

Toxys is a Dutch biotech company that offers a broad spectrum of
innovative in vitro toxicology solutions. Toxys is an expert
in the field of genetic and developmental toxicology with a focus on
Mode-of-Action. We are dedicated to bringing relevant information to our
clients on potential human health hazards of novel and existing drugs,
chemicals and other substances.

Toxys has developed the unique ToxTracker® and ReproTracker® assays.
ToxTracker provides mechanistic insight into undesired properties of
chemicals. ReproTracker® is currently under development and its
commercial launch (planned for 2019) will allow in vitro developmental
toxicity hazard identification. These assays can be particularly useful
in Mode-of-Action and Adverse Outcome Pathway (AOP) approaches for
chemical safety assessment.

We offer ToxTracker and ReproTracker as tailored service to our
customers, often in combination with standard toxicology assays or under
license and as kits for use in partner’s own laboratories. Toxys is
highly valued for its scientific expertise, high quality results and

Please visit or
contact us at for
more information.

About Charles River

Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their research
and drug development efforts. Our dedicated employees are focused on
providing clients with exactly what they need to improve and expedite
the discovery, early-stage development and safe manufacture of new
therapies for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit


Investor Contacts:

Charles River
Todd Spencer
Vice President, Investor Relations

Giel Hendriks
71 3322474

Media Contacts:

Charles River
Amy Cianciaruso
Vice President, Public Relations

Paula van Rossum
BD & Sales
+31 71 3322470

Thank you for donating to

We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.

Make a donation